Advanced Biomed (NASDAQ:ADVB) Releases Quarterly Earnings Results

Advanced Biomed (NASDAQ:ADVB) posted its quarterly earnings data on Tuesday. The company reported $0.44 earnings per share for the quarter, FiscalAI reports.

Advanced Biomed Stock Performance

NASDAQ:ADVB opened at $5.16 on Wednesday. The company has a market capitalization of $8.51 million, a PE ratio of 1.07 and a beta of 0.01. The company has a 50 day simple moving average of $7.70 and a two-hundred day simple moving average of $6.46. Advanced Biomed has a fifty-two week low of $3.61 and a fifty-two week high of $24.23.

Analyst Ratings Changes

ADVB has been the topic of several recent research reports. Wall Street Zen raised Advanced Biomed to a “hold” rating in a report on Saturday, August 22nd. Weiss Ratings lowered Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 8th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Advanced Biomed Company Profile

Advanced Biomed Inc is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for the diagnosis and treatment of cancer.

The company’s research is centered on radioligand therapies, which use targeting molecules to deliver radioactive substances directly to cancer cells. Its development programs include products designed to target prostate-specific membrane antigen (PSMA), an established target in prostate cancer.

Advanced Biomed’s programs remain subject to clinical development and regulatory review.